ANNX

AnnexonB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

ANNX has a real 2026 catalyst stack: ARCHER II topline data, FORWARD-derived U.S./EU package progression in GBS, and ANX1502 proof-of-concept progress, while current cash is guided into 2H27 [#IR-2026-03-30] [#10-K-2026-03-30].

Posture

Constructive

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta -3.6.

What can break

ARCHER II Phase 3 failure or ambiguous efficacy signal in GA

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $6.50 · Bull $11.00 · Bear $3.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net —

Target $15.11

Why

Momentum70 · Δ7d +32.3

Value41 · Δ7d -0.1

Sentiment62 · Δ7d -3.6

So what

Strength-led posture. Favor watchlist adds and disciplined entries.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Sentiment · See AI snapshot

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+32.3

Δ21d

+57.7

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-3.6

Δ21d

-7.6

Why this grade

Composite grade B. Momentum 70.2 / Value 41.1 / Sentiment 62.0

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$950.29M

Beta

1.17

Shares Out

163.84M

P/E (TTM) · Derived

-4.3

P/S (TTM)

P/FCF (TTM) · Derived

-5.22

Rev YoY

EPS YoY

-38.1%

Gross Margin

Op Margin

Net Debt

-$212.14M

Current Ratio

6.35

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology